J&J's billion dollar punt on anti-amyloid antibody.
Sheridan
Cormac
C
D000544:Alzheimer Disease / Q000191:economics / Q000628:therapy*; D000682:Amyloid / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4 / Q000235:genetics; D001921:Brain / Q000473:pathology; D002986:Clinical Trials as Topic / Q000191:economics; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D051379:Mice
D000682:Amyloid; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4; C545458:bapineuzumab